E-LIB Suche - Ergebnisse für: Ahmann, A.

1

Proportion of participants with type 2 diabetes achieving a..:

Ji, Linong ; Ahmann, A. J. ; Ahrén, B....
Diabetes, Obesity and Metabolism. 26 (2023) 1 - p. 233-241 , 2023

Link: https://doi.org/10.1111/..

2

Comparative efficacy, safety, and cardiovascular outcomes w..:

Aroda, V.R. ; Ahmann, A. ; Cariou, B....
Diabetes & Metabolism. 45 (2019) 5 - p. 409-418 , 2019

Link: https://doi.org/10.1016/..

3

Méta-analyse des études SUSTAIN 1–5 : amélioration du contr..:

Cariou, B. ; Ahmann, A. ; Francis Chow, F.C....
Annales d'Endocrinologie. 78 (2017) 4 - p. 295 , 2017

Link: https://doi.org/10.1016/..

4

A Phase 1 Trial of Ketogenic Diet With Concurrent Chemoradi..:

Anderson, C.M. ; Loth, E. ; Opat, E....
International Journal of Radiation Oncology*Biology*Physics. 94 (2016) 4 - p. 898 , 2016

Link: https://doi.org/10.1016/..

5

Efficacy and safety of liraglutide versus placebo added to ..:

Ahmann, A. ; Rodbard, H. W. ; Rosenstock, J....
Diabetes, Obesity and Metabolism. 17 (2015) 11 - p. 1056-1064 , 2015

Link: https://doi.org/10.1111/..

6

P302 Profils glycémiques enregistrés en mesure continue (CG..:

Gourdy, P. ; Bailey, T. ; Rodbard, D....
Diabetes & Metabolism. 41 (2015) - p. A109 , 2015

Link: https://doi.org/10.1016/..

7

P292 Efficacité et tolérance de l'adjonction du liraglutide..:

Bouzidi, A. ; Lahtela, J. ; Ahmann, A....
Diabetes & Metabolism. 41 (2015) - p. A106-A107 , 2015

Link: https://doi.org/10.1016/..

8

PO410 EFFICACY AND SAFETY OF LIRAGLUTIDE VS PLACEBO WHEN AD..:

Ahmann, A. ; Rosenstock, J. ; Rodbard, H....
Diabetes Research and Clinical Practice. 106 (2014) - p. S254-S255 , 2014

Link: https://doi.org/10.1016/..

9

Insulin Therapy Guided by Patient-Specific Insulin Resistan..:

Caddell, K.A. ; Komanapalli, C.B. ; Drynan, K....
Journal of Surgical Research. 158 (2010) 2 - p. 309 , 2010

Link: https://doi.org/10.1016/..

10

Morning glucose correlates poorly with daily mean glucose i..:

Hagg, D ; Smith, S ; Oveson, K...
Critical Care. 13 (2009) Suppl 1 - p. P115 , 2009

Link: https://doi.org/10.1186/..

11

Safety Profile and Metabolic Effects of 14 Days of Treatmen..:

SCHWARTZ, S ; RENDELL, M ; AHMANN, A...
Clinical Therapeutics. 30 (2008) 6 - p. 1081-1088 , 2008

Link: https://doi.org/10.1016/..

12

Diurnal and other variations in blood glucose in intensive ..:

Smith, S ; Oveson, K ; Strauss, W..
Critical Care. 11 (2007) Suppl 2 - p. P133 , 2007

Link: https://doi.org/10.1186/..

13

Phase II Trial of Recombinant Tumor Necrosis Factor in Diss..:

Feldman, E. R. ; Creagan, E. T. ; Schaid, D. J..
American Journal of Clinical Oncology. 15 (1992) 3 - p. 256-259 , 1992

Link: https://doi.org/10.1097/..

14

Recombinant Interferons in the Management of Advanced Malig..:

Creagan, E. T. ; Schaid, D. J. ; Ahmann, D. L..
American Journal of Clinical Oncology. 11 (1988) 6 - p. 652-659 , 1988

Link: https://doi.org/10.1097/..

15

Phase II evaluation of L-alanosine (NSC-153353) for patient..:

Creagan, E. T. ; Long, H. J. ; Ahmann, D. L..
American Journal of Clinical Oncology. 7 (1984) 5 - p. 543-544 , 1984

Link: https://doi.org/10.1097/..